Literature DB >> 26361278

Causes of 30-day readmission after aneurysmal subarachnoid hemorrhage.

Jacob K Greenberg1, Chad W Washington1, Ridhima Guniganti1, Ralph G Dacey1, Colin P Derdeyn1,2,3, Gregory J Zipfel1,2.   

Abstract

OBJECTIVE: Hospital readmission is a common but controversial quality measure increasingly used to influence hospital compensation in the US. The objective of this study was to evaluate the causes for 30-day hospital readmission following aneurysmal subarachnoid hemorrhage (SAH) to determine the appropriateness of this performance metric and to identify potential avenues for improved patient care.
METHODS: The authors retrospectively reviewed the medical records of all patients who received surgical or endovascular treatment for aneurysmal SAH at Barnes-Jewish Hospital between 2003 and 2013. Two senior faculty identified by consensus the primary medical/surgical diagnosis associated with readmission as well as the underlying causes of rehospitalization.
RESULTS: Among 778 patients treated for aneurysmal SAH, 89 experienced a total of 97 readmission events, yielding a readmission rate of 11.4%. The median time from discharge to readmission was 9 days (interquartile range 3-17.5 days). Actual hydrocephalus or potential concern for hydrocephalus (e.g., headache) was the most frequent diagnosis (26/97, 26.8%), followed by infections (e.g., wound infection [5/97, 5.2%], urinary tract infection [3/97, 3.1%], and pneumonia [3/97, 3.1%]) and thromboembolic events (8/97, 8.2%). In most cases (75/97, 77.3%), we did not identify any treatment lapses contributing to readmission. The most common underlying causes for readmission were unavoidable development of SAH-related pathology (e.g., hydrocephalus; 36/97, 37.1%) and complications related to neurological impairment and immobility (e.g., thromboembolic event despite high-dose chemoprophylaxis; 21/97, 21.6%). The authors determined that 22/97 (22.7%) of the readmissions were likely preventable with alternative management. In these cases, insufficient outpatient medical care (for example, for hyponatremia; 16/97, 16.5%) was the most common shortcoming.
CONCLUSIONS: Most readmissions after aneurysmal SAH relate to late consequences of hemorrhage, such as hydrocephalus, or medical complications secondary to severe neurological injury. Although a minority of readmissions may potentially be avoided with closer medical follow-up in the transitional care environment, readmission after SAH is an insensitive and likely inappropriate hospital performance metric.

Entities:  

Keywords:  BJH = Barnes-Jewish Hospital; CMS = Centers for Medicare and Medicaid Services; COPD = chronic obstructive pulmonary disease; DVT = deep vein thrombosis; IQR = interquartile range; SAH = subarachnoid hemorrhage; UTI = urinary tract infection; health care; hospital readmission; patient readmission; qualitative research; quality indicators; subarachnoid hemorrhage; vascular disorders

Mesh:

Year:  2015        PMID: 26361278      PMCID: PMC5729751          DOI: 10.3171/2015.2.JNS142771

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  31 in total

1.  Thirty-day readmissions--truth and consequences.

Authors:  Karen E Joynt; Ashish K Jha
Journal:  N Engl J Med       Date:  2012-03-28       Impact factor: 91.245

Review 2.  Interventions to reduce 30-day rehospitalization: a systematic review.

Authors:  Luke O Hansen; Robert S Young; Keiki Hinami; Alicia Leung; Mark V Williams
Journal:  Ann Intern Med       Date:  2011-10-18       Impact factor: 25.391

3.  Rehospitalizations among patients in the Medicare fee-for-service program.

Authors:  Stephen F Jencks; Mark V Williams; Eric A Coleman
Journal:  N Engl J Med       Date:  2009-04-02       Impact factor: 91.245

4.  Characteristics of elderly people readmitted to the hospital during the first year after stroke. The Göteborg 70+ stroke study.

Authors:  Lisbeth Claesson; Gunilla Gosman-Hedström; Birgitta Lundgren-Lindquist; Björn Fagerberg; Christian Blomstrand
Journal:  Cerebrovasc Dis       Date:  2002       Impact factor: 2.762

5.  Analysis of 30-day readmissions among neurosurgical patients: surgical complication avoidance as key to quality improvement.

Authors:  Colin C Buchanan; Estebes A Hernandez; Jody M Anderson; Justin A Dye; Michelle Leung; Farzad Buxey; Marvin Bergsneider; Nasim Afsar-Manesh; Nader Pouratian; Neil A Martin
Journal:  J Neurosurg       Date:  2014-05-16       Impact factor: 5.115

6.  Readmission after stroke in a hospital-based registry: risk, etiologies, and risk factors.

Authors:  Huey-Juan Lin; Wei-Lun Chang; Mei-Chiun Tseng
Journal:  Neurology       Date:  2011-01-05       Impact factor: 9.910

7.  Factors associated with hydrocephalus after aneurysmal subarachnoid hemorrhage.

Authors:  J P Sheehan; R S Polin; J M Sheehan; M K Baskaya; N F Kassell
Journal:  Neurosurgery       Date:  1999-11       Impact factor: 4.654

8.  Comprehensive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial.

Authors:  M D Naylor; D Brooten; R Campbell; B S Jacobsen; M D Mezey; M V Pauly; J S Schwartz
Journal:  JAMA       Date:  1999-02-17       Impact factor: 56.272

9.  Independent predictors of late hydrocephalus in patients with aneurysmal subarachnoid hemorrhage--analysis by multivariate logistic regression model.

Authors:  Yutaka Hirashima; Hideo Hamada; Nakamasa Hayashi; Naoya Kuwayama; Hideki Origasa; Shunro Endo
Journal:  Cerebrovasc Dis       Date:  2003       Impact factor: 2.762

10.  Predictors of 30-day readmission after subarachnoid hemorrhage.

Authors:  Mandeep Singh; James C Guth; Eric Liotta; Adam R Kosteva; Rebecca M Bauer; Shyam Prabhakaran; Neil Rosenberg; Bernard R Bendok; Matthew B Maas; Andrew M Naidech
Journal:  Neurocrit Care       Date:  2013-12       Impact factor: 3.210

View more
  7 in total

1.  Preventable Readmissions and Predictors of Readmission After Subarachnoid Hemorrhage.

Authors:  John W Liang; Laura Cifrese; Lili Velickovic Ostojic; Syed O Shah; Mandip S Dhamoon
Journal:  Neurocrit Care       Date:  2018-12       Impact factor: 3.210

2.  Nonindex Readmission After Ruptured Brain Aneurysm Treatment Is Associated with Higher Morbidity and Repeat Readmission.

Authors:  Austin M Tang; Joshua Bakhsheshian; Li Ding; Casey A Jarvis; Edith Yuan; Ben Strickland; Steven L Giannotta; Arun Amar; Frank J Attenello; William J Mack
Journal:  World Neurosurg       Date:  2019-07-05       Impact factor: 2.104

3.  Potentially Preventable 30-Day Hospital Readmissions at a Children's Hospital.

Authors:  Sara L Toomey; Alon Peltz; Samuel Loren; Michaela Tracy; Kathryn Williams; Linda Pengeroth; Allison Ste Marie; Sarah Onorato; Mark A Schuster
Journal:  Pediatrics       Date:  2016-08       Impact factor: 7.124

4.  Predictors of 30-day readmission after aneurysmal subarachnoid hemorrhage: a case-control study.

Authors:  Jacob K Greenberg; Ridhima Guniganti; Eric J Arias; Kshitij Desai; Chad W Washington; Yan Yan; Hua Weng; Chengjie Xiong; Emily Fondahn; DeWitte T Cross; Christopher J Moran; Keith M Rich; Michael R Chicoine; Rajat Dhar; Ralph G Dacey; Colin P Derdeyn; Gregory J Zipfel
Journal:  J Neurosurg       Date:  2016-08-05       Impact factor: 5.115

5.  Advanced Age and Post-Acute Care Outcomes After Subarachnoid Hemorrhage.

Authors:  Corey R Fehnel; William B Gormley; Hormuzdiyar Dasenbrock; Yoojin Lee; Faith Robertson; Alexandra G Ellis; Vincent Mor; Susan L Mitchell
Journal:  J Am Heart Assoc       Date:  2017-10-24       Impact factor: 5.501

6.  Towards a patient journey perspective on causes of unplanned readmissions using a classification framework: results of a systematic review with narrative synthesis.

Authors:  R G Singotani; F Karapinar; C Brouwers; C Wagner; M C de Bruijne
Journal:  BMC Med Res Methodol       Date:  2019-10-04       Impact factor: 4.615

7.  Annual incidences and predictors of 30-day readmissions following spontaneous intracerebral hemorrhage from 2010 to 2014 in the United States: A retrospective Nationwide analysis.

Authors:  Haydn Hoffman; Taylor Furst; Muhammad S Jalal; Lawrence S Chin
Journal:  Heliyon       Date:  2019-12-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.